One CRISPR treatment cut “bad” cholesterol in half for a full year
A first-in-human Phase 1 clinical trial from Cleveland Clinic found that a single infusion of a CRISPR-Cas9 gene-editing therapy produced lasting reductions in LDL (“bad”) cholesterol and triglycerides in people with lipid disorders that had not responded adequately to medications. The study followed 15 patients for one year to determine whether the cholesterol and triglyceride … Read more